<?xml version="1.0" encoding="UTF-8"?>
<p>In 2009, the Chinese government recommended traditional Chinese medicine (TCM) prescriptions of Lianhua-Qingwen capsule (LQ) as a candidate formula to treat and control the H1N1 pandemic. This new formula is a natural herbal medicine developed from two classical TCM formulae, 
 <italic>Yinqiao San</italic> and 
 <italic>Maxing Shigan Tang,</italic> which have been used historically for treatment of influenza-like illness in China [
 <xref rid="B13" ref-type="bibr">13</xref>]. When a randomized, double-blind, positive-controlled clinical trial of LQ anti-influenza A (H1N1) virus treatment was performed in China, the results confirmed that it was able to alleviate the symptoms significantly and achieve the same effect as oseltamivir [
 <xref rid="B14" ref-type="bibr">14</xref>]. LQ was approved for clinical trials as treatment for influenza infection by the FDA in 2016. In addition, our previous results also demonstrated that LQ could inhibit different strains of influenza A viruses and that it also suppressed virus-induced NF-kB activation and alleviated virus-induced cytokine expression [
 <xref rid="B15" ref-type="bibr">15</xref>].
</p>
